The MEK/ERK Network as a Therapeutic Target in Human Cancer.

Area of Science:

• Molecular Biology
• Cancer Research
• Signal Transduction

Background:

• The RAS-RAF-MEK-ERK pathway (MAPK cascade) is crucial for cell functions, and its dysregulation drives many cancers, especially melanomas.
• Mutations in RAS and RAF are common drivers of cancer, but acquired drug resistance necessitates exploring other pathway components.

Purpose of the Study:

• To elucidate the roles of MEK and ERK in MAPK signaling and their activation mechanisms.
• To review current strategies targeting MEK and ERK and explore alternative approaches for overcoming drug resistance.

Main Methods:

• Review of existing literature on MAPK pathway components, activation, and therapeutic targeting.
• Analysis of MEK and ERK roles in overcoming resistance mechanisms in MAPK-driven cancers.

Main Results:

• MEK and ERK are terminal kinases in the MAPK cascade, with increasing relevance in acquired drug resistance.
• Targeting MEK and ERK shows promise in overcoming resistance to therapies for RAS- and RAF-mutated cancers.

Conclusions:

• Understanding MEK and ERK interactions and activation is key to developing effective cancer therapies.
• Further research into targeting MEK and ERK is essential for combating drug resistance in MAPK-mediated cancers.